Product image of Glusod (Empagliflozin) supplied by GNH India

Glusod

Active Ingredient:
Empagliflozin
Origin:
EU

Glusod (Empagliflozin)

Glusod is a prescription medication whose active ingredient is empagliflozin, an SGLT2 inhibitor. It is supplied as an oral tablet (strength not specified) and is marketed in the European Union. Empagliflozin works by blocking the sodium‑glucose co‑transporter 2 in the kidney, which reduces glucose reabsorption and promotes urinary glucose excretion. Glusod is used under medical supervision for approved diabetic and cardiovascular and renal conditions as part of comprehensive care.

Manufacturer / TM Owner

Medochemie Ltd.

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Glusod (empagliflozin) is indicated for several chronic conditions where glucose control and organ protection are needed.

  • Type 2 diabetes mellitus to improve glycemic control.
  • Heart failure with reduced ejection fraction to reduce risk of cardiovascular death and hospitalization.
  • Diabetic kidney disease to slow progression of renal impairment.
  • Adjunct to diet and exercise in patients inadequately controlled on other antidiabetic agents.
  • Patients with high cardiovascular risk to provide additional cardioprotective benefit.

Side Effects

The safety profile of Glusod reflects the class effects of SGLT2 inhibitors, with most patients experiencing mild, reversible events, while rare serious reactions may require medical attention.

Common

  • Increased urinary frequency or volume.
  • Genital mycotic infections (e.g., yeast infections).
  • Mild dehydration or thirst.
  • Lower limb swelling or edema.

Serious

  • Ketoacidosis (euglycemic diabetic ketoacidosis).
  • Acute kidney injury.
  • Severe urinary tract infection.
  • Hypotension or orthostatic dizziness.

Precautions & Warnings

Before initiating Glusod, clinicians should evaluate patient-specific factors and monitor for conditions that could be worsened by SGLT2 inhibition.

  • Assess renal function; avoid use in severe impairment.
  • Monitor volume status and electrolytes, especially in patients on diuretics.
  • Caution in elderly patients due to dehydration risk.
  • Evaluate for history of recurrent genital or urinary infections.
  • Consider pregnancy and lactation status; safety data are limited.
  • Review cardiovascular status, especially in heart failure patients.

Avoid Interactions

Glusod may interact with other medicines that affect glucose, blood pressure, or renal function, requiring dose adjustments or monitoring.

Avoid

  • Concurrent use with insulin or insulin secretagogues without dose reduction (risk of hypoglycemia).
  • Combination with strong diuretics leading to excessive volume depletion.

Use with caution

  • Co‑administration with ACE inhibitors or ARBs (monitor renal function).
  • Use with other SGLT2 inhibitors (no added benefit, increased adverse risk).
  • Concomitant use of NSAIDs (potential renal impact).

Frequently Asked Questions

Glusod contains empagliflozin, which inhibits the sodium‑glucose co‑transporter 2 (SGLT2) in the proximal renal tubules, reducing glucose reabsorption and increasing urinary glucose excretion.

Yes, empagliflozin is often added to metformin when glycemic control is insufficient, but dose adjustments and monitoring are recommended by a healthcare professional.

Glusod is indicated for heart failure with reduced ejection fraction to lower the risk of cardiovascular death and hospitalisation, based on clinical trial evidence.

Renal function should be evaluated; Glusod is generally avoided in patients with severe renal impairment (eGFR below the threshold defined in local guidelines).

Common side effects include increased urination, genital yeast infections, mild dehydration, and peripheral edema.

By promoting osmotic diuresis, empagliflozin can lead to modest reductions in systolic and diastolic blood pressure.

Physicians may advise temporary discontinuation before major surgery to reduce the risk of ketoacidosis and dehydration, but decisions are individualized.

Although rare, empagliflozin can precipitate euglycemic diabetic ketoacidosis, especially in patients with insulin deficiency or prolonged fasting.

Safety data for empagliflozin in pregnancy are limited; it is generally not recommended unless the potential benefit outweighs the risk.

Regular monitoring of renal function, electrolytes, blood glucose, and signs of infection is advised during treatment.

Concurrent use of NSAIDs may affect renal function; clinicians should monitor kidney parameters when these drugs are combined.

Glusod is a prescription‑only medication in the European Union and must be prescribed by a qualified healthcare provider.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Empagliflozin

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT